EP1896853A1 - Matiere de support et procede de fabrication et d'utilisation de ladite matiere - Google Patents

Matiere de support et procede de fabrication et d'utilisation de ladite matiere

Info

Publication number
EP1896853A1
EP1896853A1 EP06763813A EP06763813A EP1896853A1 EP 1896853 A1 EP1896853 A1 EP 1896853A1 EP 06763813 A EP06763813 A EP 06763813A EP 06763813 A EP06763813 A EP 06763813A EP 1896853 A1 EP1896853 A1 EP 1896853A1
Authority
EP
European Patent Office
Prior art keywords
affinity ligands
carrier material
base material
reactive groups
chemically reactive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06763813A
Other languages
German (de)
English (en)
Inventor
Thomas Ehben
Mitja Schonecke
Christian Zilch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioville GmbH
Original Assignee
Siemens AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siemens AG filed Critical Siemens AG
Publication of EP1896853A1 publication Critical patent/EP1896853A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G01N33/54333—Modification of conditions of immunological binding reaction, e.g. use of more than one type of particle, use of chemical agents to improve binding, choice of incubation time or application of magnetic field during binding reaction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00—Magnetic particle immunoreagent carriers
    • G01N2446/20—Magnetic particle immunoreagent carriers the magnetic material being present in the particle core
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00—Magnetic particle immunoreagent carriers
    • G01N2446/60—Magnetic particle immunoreagent carriers the magnetic material being dispersed in a medium other than the main solvent prior to incorporation into the polymer particle
    • G01N2446/66—Magnetic material dispersed in surfactant

Definitions

  • the present invention relates to a carrier material for use in a diagnostic method, a method for producing the carrier material and a use of Trä ⁇ germaterials.
  • Magnetic, polymeric support materials are used to an increasing extent in biochemistry and medical diagnostics for the separation of cells, proteins and nucleic acids.
  • the use of magnetic carrier materials offers the advantage over conventional separation methods that the loaded carrier materials can be easily and quickly separated from the remaining constituents of a sample by means of magnetic forces.
  • Magnetic bead-shaped or spherical polymer particles based on polyvinyl alcohol with a narrow particle size distribution in a range below 10 ⁇ m have proven to be particularly suitable for such separation methods (WO 97104862).
  • nucleic acids and proteins can be isolated from their na ⁇ -natural environment only with increased effort. This is mainly because stringent mechanical, chemical and biological cell lysis methods must be used to isolate the nucleic acids and proteins from the cell nucleus or the cell membrane or organelles.
  • the corresponding biological samples usually contain other, solid and / or dissolved compounds, such as other proteins and constituents of the cell framework, which may affect the isolation. Additionally aggravating is the fact that the nucleic acids or proteins are very often only present in low concentrations in the biological sample to be examined. Nevertheless, in order to be able to exploit the advantages of isolating nucleic acids from biological samples using magnetic particles, it has been proposed inter alia to isolate nucleic acids with the aid of magnetic particles having a glass surface which is essentially free of pores (WO 96141811). These particles have a reduction of certain concentrations ⁇ their glass surface must have a certain ie together ⁇ men attitude, len to the desired efficacy to erzie ⁇ . In addition, a relatively expensive process for manufacturing these particles provide necessary to provide the necessary Sinte ⁇ the glass surface tion to achieve.
  • the target molecule has to be tied, while contaminating components of the sample are dissolved in another, liquid phase ge ⁇ . After various washing procedures, the target molecule must then be such as to be replaced by the solid phase ⁇ by changing the liquid phase.
  • the repeated Me ⁇ serving exchange is both very hard material, on the other hand the product yields fluctuate with each additional process step, so that a quantitative calibration difficult.
  • integrated analysis ⁇ procedures for example, lab-on-a-chip systems in which the preparation and analysis of samples largely automatic ⁇ table expires, a review of the individual process steps eats often not possible to strengthen so that deviations in each individual process steps and can result in large variations in the analysis result.
  • the magnetic beads are provided with affinities tucisliganden or other surface modifications, and therefore capable of a certain solution Biomole ⁇ molecules, such as DNA bind to their surface.
  • Typi cally ⁇ is given genzrschreibchen in a purification process of a suspension of magnetic beads in the sample to be separated in an REA. After an incubation period of several minutes to allow binding of the affinity ligand to the biological molecule sought, a magnetic field is applied which separates the particles by attachment to a wall of the tube. The supernatant is discarded and the particles are washed at least once more.
  • ⁇ body with a fluorescent marker or magnetic beads For isolation of eukaryotic or prokaryotic cells or viruses, it is known, for example, specific anti ⁇ body with a fluorescent marker or magnetic beads to LAD PelN.
  • the antibody is generally monoclonal and directed against specific binding sites, for example against a surface receptor molecule of a corresponding antigen of the cell or virus.
  • FACS Fluorescense Activated Cell Sorter
  • Permanentmag ⁇ By coupling the antibody with the respective binding site of the desired cells or viruses are selected and screened Neten for example using a FACS (Fluorescense Activated Cell Sorter) or a Permanentmag ⁇ .
  • FACS Fluorescense Activated Cell Sorter
  • Permanentmag ⁇ the sorting operation both as a so-called "positive selection” can be carried out, wherein the labeled cells or viruses are further processed.
  • Runaway ⁇ leads wherein the labeled cells are removed and the remaining cells are further processed.
  • quantification of the cells or viruses is possible, so that quantities of reagents required for further processing can be calculated.
  • DE 101 11 520 B4 discloses a process for the purification of biomolecules with the aid of magnetic particles, in which, in particular, smaller quantities of liquid can be purified to a large extent by automated means. It is described ⁇ ben to promote the suspension with magnetic particles through a pipeline that passes a strong magnetic field. In this case, flow can be given a suitable design of the diameter, speed and magnetic field strength, the magnetic particles left in the flow at the wall of the pipeline till ⁇ . The supernatant is discarded by emptying the tubing or collected in a receiver. The trapped particles can now be washed by overflowing with washing solutions. The magnetic particles may be held in the tubing during the washing procedure or suspended and redeposited.
  • the pipeline is to be designed so that the handling of small amounts of liquid is possible with less than 50 microns.
  • the method described is particularly suitable for the purification of DNA or RNA. Which are available in solution at the end of the process.
  • the stationary DNA or RNA can be automatically introduced into a corre ⁇ sponding analysis system.
  • the automation can be done for example via a pipetting robot. If the DNA is to be detected via a sequence-specific hybridization, it is also proposed to additionally lead the pipeline via a heating device in order to achieve denaturation of the DNA double strand. However, in order to obtain the DNA analysis described, it is still necessary to extract the DNA from the sample by means of non-described method steps.
  • Magnetic beads are not only suitable for the purification of samples, but can also be used for other purposes.
  • US 2004/0219066 A1 describes a device by means of which different particles can be sorted. The particles are bound to different magnetic beads, which have different magnetic moments. In a per ⁇ a magnetic field gradient is generated process chamber, which will see the magnetic beads due to their different magnetic moments moving in different cardboard boxes. The ver ⁇ different particles are indistinguishable so on differently designed magnetic beads.
  • Components of a sample are connected.
  • An enzyme is coupled to the bound components of the sample and an added ⁇ input substrate cleaved by the enzyme. From the substrate emerges a molecule that allows a redox cycling process. In this way the part of the sample after ⁇ is weisbar.
  • paramagnetic magnetic beads for the detection of DNA.
  • paramagnetic magnetic beads are located on a magnetorestrictive sensor catcher molecules that are complementary to the DNA to be detected. Is in the examined sample, the DNA to be detected is present, a hybridization takes ⁇ tion between the DNA to be detected and the capture molecules instead of.
  • the hybridized DNA is labeled with a biotin to which streptavidin-coated magnetic beads couple.
  • the biotin label is inserted into the DNA to be detected by means of an upstream PCR using biotin-labeled primers. After coupling with the paramagnetic beads, they are magnetized via an applied magnetic field and their stray field is measured by the magnetoresistive sensor. This indirectly provides a quantitative detection of the DNA in the sample.
  • the polyvinyl alcohol particles are prepared by adding certain emulsifier mixtures to the oil phase of the water-in-oil emulsion.
  • Suitable emulsifiers which are added to the oil phase as additives are propylene oxide
  • Ethylene oxide block copolymers sorbitan fatty acid esters, Kom ⁇ plexmischester of pentaerythritol fatty acid esters with citric acid, polyethylene glycol castor oil derivatives, block copolymers of castor oil derivatives, polyethylene glycols, modified polyesters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene len polyoxypropylene Ethylene diamine block copolymers, polyglycerol derivatives, polyoxyethylene alcohol derivatives, alkylphenyl polyethylene glycol derivatives, polyhydroxy fatty acid-polyethylene glycol block copolymers, polyethylene glycol ether derivatives. Substances of this type are commercially available.
  • a mixture of at least two, preferably three to four, of the surface-active substances mentioned is added to the oil phase.
  • a lipophilic emulsifier is mixed with at least one emulsifier, the semi-hydrophilic properties egg ⁇ having, that is both water and oil soluble.
  • Emulsifiers that fulfill the latter properties are, for. B.: Ethylene oxide-propylene oxide block copolymer derivatives with predominantly ⁇ thylenoxid- share, polyethylene glycol hexadecyl ether, shorter-chain polyoxyethylene sorbitan fatty acid esters, polyethylene glycols or besideerketti ⁇ ge sorbitan fatty acid esters.
  • concentration of the emulsifiers in the oil phase is usually 2-6 vol.%, Preferably
  • the polymer droplets are Emulgatormischun- gen advantageous which contain at least two lipophilic components and one semi-hydrophilic emulsifier.
  • the concentration of the semi-hydrophilic emulsifier is in the
  • the particles show a pear-shaped form.
  • emulsifiers for the oil phase special surface-active substances which are soluble in the aqueous polymer phase also contribute to improving the emulsion quality, in particular of low molecular weight polyvinyl alcohol solutions (Mowiol, Clariant GmbH, Frankfurt am Main, FRG).
  • ionic emulsifiers examples include serum albumin, gelatin, aliphatic and aromatic sulfonic acid derivatives, polyethylene glycols, poly-N-vinylpyrrolidone or cellulose acetate butyrate.
  • the amounts of emulsifiers used are as a rule 0.01-2% by weight, based on the polymer phase, the concentration of the ionic emulsifiers consistently between 0.01 and 0.05 wt.%.
  • the skilled person is aware of influences of the stirring speeds as well as concentrations and viscosities of the two phases on the particle size. In order to realize the preferred particle sizes of 0.5-10 ⁇ m, stirring speeds of 1500-2000 rpm are required, using conventional two-blade propeller stirrers.
  • magnetic particles which are encapsulated in the polyvinyl alcohol matrix during the process it is possible in principle to use those ferromagnetic or superparamagnetic colloids which have a corresponding particle size and generally have a magnetic saturation of 50 to 400 gauss.
  • Another requirement which the magnetic particles have to fulfill is the dispersibility in the aqueous polymer phase in which the polyvinyl alcohol is present. In the subsequent emulsion in the organic phase, the magnetic colloids are then simultaneously entrapped in the polymer droplets.
  • Suitable magnetic colloids are preferably magnetites with particle sizes of 10-200 nm. Such substances are for. B. commercially available under the trade name Bayferrox or Ferrofluidics. Since the production is such Kolloi- de general prior art, the magnetic part ⁇ chen can also by the known methods such. By Shinkai et al. , Biocatalysis, Vol. 5, 1991, 61, Reimers and Khalafal-Ia, Br. Patent 1,439,031 or Kondo et al. , Appl. Microbiol. Biotechnol., VoI 41, 1994, 99, are prepared. The concentrations of the colloids in the polymer phase are, in each case based on this phase, usually Zvi ⁇ 4 and 14.
  • the magnetic polyvinyl alcohol support material can then be obtained from the suspension by the methods known per se to the person skilled in the art, for example by filtration and washing.
  • affinity ligands For functionalization, it is known to provide the support material with affinity ligands on the surface. For this, it is generally necessary to attach chemically reactive groups on the surface to which the affinity ligands are then bound. These groups can be carried out, for example, as tosyl, hydroxyl, aldehyde or carboxyl, amino, thiol or epoxy groups. They can generally be provided by treating uncoated monodisperse superparamagnetic particles to give them a surface layer of such a functional one
  • the described carrier materials can be designed as a filter, membrane or particles.
  • the magnetic carrier material is preferably in the form of bead-shaped or spherical particles, these particles preferably having a particle size of 0.2 to 50 ⁇ m, more preferably 0.5 to 5 ⁇ m. In addition to the before ⁇ preferably bead and spherical shape of the particles should whose particle size distribution are within the narrowest possible range.
  • the support materials are preferably produced in particle form by reacting the polyvinyl alcohol support material with an organic silane compound. Subsequently, the silanized particles are reacted with affinity ligands.
  • affinity ligands used in affinity chromatography can be coupled as affinity ligands.
  • affinity ligands examples of these are: protein A, protein G, protein L, streptavidin, biotin, heparin, antibodies, serum albumin, gelatin, lysine, concanavalin A, oligosaccharides, oligonucleotides, polynucleotides, protein-binding metal ions, lectins, aptamers or enzymes.
  • affinity ligands are: protein A, protein G, protein L, streptavidin, biotin, heparin, antibodies, serum albumin, gelatin, lysine, concanavalin A, oligosaccharides, oligonucleotides, polynucleotides, protein-binding metal ions, lectins, aptamers or enzymes.
  • the specific separations that can be performed with such affinity matrices are well known in the art.
  • Object of the present invention is to provide improved Trä ⁇ germaterialien available that allow largely automatic diagnostic procedures.
  • a carrier material with the features of claim 1. It consists of a base material with a surface equipped with at least two different affinity ligands. These refer to affinity ligands Various ⁇ ne varieties, not more than one copy of a variety of affinity ligands.
  • the design of the carrier material with at least two different Affini ⁇ tiquessliganden increases the range of applications compared to known embodiments.
  • affinity ligands of the abovementioned types can be used. Generally, each type of affinity ligand will have a plurality of surface-bound copies.
  • the carrier material according to the invention can be used within ei ⁇ nes diagnostic method for different, especially sequentially performed tasks so that manual operations are largely automated can. This can simplify diagnostic procedures.
  • known support materials with only one kind of affinity ligands are only suitable for binding one cell type.
  • carrier materials are required in a complex analysis procedure, in which several different cell types are to be detected or in which DNA obtained from a cell is further processed.
  • the problem here is that already used and no longer required carrier materials are dragged into subsequent process steps and interfere with them. This is particularly problematic in the case of magnetic or magnetizable carrier materials, since they are particularly easy to carry off and have a disturbing effect.
  • This carrier material of the invention offers the advantage that there are examples of play during the performance of an analysis Trä ⁇ germaterialien in various process steps can be used. As a result of the multiple use of the carrier material according to the invention, no superfluous carrier material already used in one process step is carried off into subsequent process steps.
  • the inventive Trä ⁇ germaterial process steps can be avoided is where excess carrier material removed from the process.
  • a first of the affinity ligands has binding properties for a biological structure and a second of the affinity ligands has binding properties for a biological molecule.
  • biological structure is to be understood in particular below as bacteria, cells and viruses.
  • biological molecule is to be understood below to mean in particular DNA, RNA, proteins, carbohydrates and lipids
  • any types of molecules are to be understood which can be understood, for example, within a single molecule Analysis of the sample to be detected. These include, for example, organic and inorganic toxins.
  • the surface is equipped with further affinity ligands with binding eigenstates for further biological structures. This is particularly important for diagnostic procedures in which a molecule occurs in different structures.
  • the corresponding different structures can be extracted from the sample and purified. After extraction of the molecules, they can be further processed.
  • the surface is equipped with further affinity ligands with binding properties for further biological molecules. This is important in processes where different molecules occur in different instances of a structure. Accordingly, after extracting the various molecules from the specimens of the structure, the molecules can be processed further with the aid of the carrier material.
  • the first of the affinity ligands for a specific protein and the second of the affinity ligands for a specific nucleic acid sequence binding properties is of particular interest in a method for detecting the nucleic acid sequence.
  • the nucleic acid sequence may, for example, characterize a particular bacterium. By a detection of the nucleic acid sequence in an analytical method, the bacterium can be detected.
  • the nucleic acid sequence is typically present within the bacterium. In the analysis method, for example, the bacterium is first bound via a cell receptor to the first affinity ligand.
  • the first affinity ligand is an anti ⁇ body and the second affinity ligand is designed as a Oligonukleo- tid as an antibody or portion.
  • oligonucleotides are to be understood as meaning single-stranded nucleic acid molecules.
  • This embodiment of the affinity ligands can be produced in a particularly simple and specific manner and applied to the surface of the base material. At the same time it offers very specific binding properties for biological structures and, for example, DNA, so that a high degree of specification is achieved. In this case, oligonucleotides are founded with different sequence of bases as different affinity ligands ⁇ take as they have for different DNA sequences Bindungsei- properties.
  • the base material contains paramagnetic particles.
  • the carrier material may be formed, for example, as a magnetic bead.
  • the method-related object is achieved by a method having the features of claim 15 or 19.
  • any affinity ligand on the surface of the base material can be brought to ⁇ . It is important that always only a portion of the reactive groups is occupied with affinity ligands, so that other types of ligands can be applied.
  • the base material is more gene in Be Anlagenungslösun- introduced in each of which the affinity ligand vorlie ⁇ gene that are linked to further units of the chemically reactive groups. This makes it easy to produce multifunctional carrier materials for a diagnostic procedure.
  • the base material is introduced into a further coating solution in which proteins are present, which are attached to the bind unoccupied chemically reactive groups.
  • the carrier material is preferably used for nucleic acid analysis, nucleic acid preparation and / or nucleic acid detection.
  • 1 is a schematic representation of an already known carrier material
  • 2 is a schematic representation of another already known carrier material
  • Fig. 4 is a schematic representation of an alternative embodiment of the invention.
  • Fig. 5 is a schematic flow diagram of a manufacturing ⁇ method for the carrier materials.
  • a substrate 1 is shown schematically. It is known per se in the form shown and is preferably used in diagnostic processes. It comprises a magnetic bead 3, which was produced, for example, by the method described above.
  • the magnetic bead 3 contains several ⁇ re superparamagnetic particles 4.
  • a surface 5 of the magnetic beads 3 is reacted with reactive groups.
  • Antibodies 7 are bound to the reactive groups 6.
  • the antibodies 7 have binding properties for a biological structure, for example a eukaryotic cell, a bacterium or a virus present in a sample to be analyzed.
  • the carrier material 1 is capable of binding the biological structure by the antibodies 7, whereby it can be manipulated by means of a magnetic field.
  • the superparamagnetic particles 4 only become magnetic when a magnetic field is present.
  • the magnetic ⁇ -Nazi properties are lost again as soon as the magnetic field is switched off. As a result, for example, a clumping of the individual magnetic beads 3, which are generally present in large numbers, prevented. As already described, the use of the magnetic field allows the desired biological structures to be separated from the sample.
  • FIG. 2 shows a further carrier material 101, which is likewise known.
  • carrier materials 101 are preferably used in nucleic acid diagnosis.
  • the carrier material 101 is similar to that shown in Figure 1 the carrier material 1 and comprises a magnetic bead 3.
  • On the surface 5 of the magnetic beads 3 are disposed reactive groups 6 are bound to de ⁇ NEN oligonucleotides 103 as affinity ligands.
  • Each of the oligonucleotides 103 is directed against a DNA to be detected, so that when the DNA is present in a sample, hybridization between the DNA and the oligonucleotides can take place.
  • the DNA to be detected is derived beispielswei ⁇ se from a virus or a cell, and is generally duplicated for the detection by PCR.
  • Ver ⁇ the DNA binding with the support material 101 is a Abtren ⁇ voltage from the rest of the sample.
  • FIG. 3 schematically shows a preferred embodiment of the invention.
  • a carrier material 201 comprises, in analogy to the already known embodiments, a magnetic bead 3 on whose surface 5 reactive groups 6 with affinity ligands are arranged.
  • both antibodies 7 and oligonucleotides 103 are provided on the magnetic bead 3.
  • the thus functionalised support material 201 can be inserted into a correspondingly shaped ⁇ Ana lysis or diagnostic process for different purposes.
  • the antibodies 7 are directed for example against a cell receptor (eg CD4) of a cell type, so are preferably monoclonal antibodies.
  • the oligonucleotides 103 ge ⁇ , oriented to a gene sequence of the cell, for example, against an activated gene in T-HeIferzeilen.
  • the sought-after cells can be separated from the sample.
  • the DNA After a cell disruption, the DNA is present in free form and can bind to the oligonucleotides 103 after denaturation and possible comminution.
  • the bound DNA may be according to known methods ⁇ separated from the sample and be detected, for example by means of a GMR or TMR sensor.
  • FIG. 4 shows an alternative embodiment of the invention.
  • the backing material 301 comprises analog to the previously beschrie ⁇ surrounded embodiments, a magnetic bead 3 on the surface thereof reactive groups 6 and affinity ligands are arranged.
  • various antibodies 7, 7a, 7b and 7c are attached to a part of the groups 6.
  • Antibodies 7, 7a, 7b and 7c are directed against various types of biological structures. These can be, for example, different cells or viruses.
  • oligonucleotides 103, 103a, 103b and 103c are bound. Oligonucleotides 103, 103a, 103b and 103c are directed against gene sequences of the structures selectable by antibodies 7, 7a, 7b and 7c.
  • a gene sequence of interest may be present in several cells, for example 16S rRNA from different bacteria.
  • a carrier material with oligonucleotides for this gene sequence and antibodies for the cell types in question is suitable for making isolation and detection in a simple manner in an analysis method possible. It also happens that different gene sequences or SNPs occur in one cell type and should be detected.
  • a suitable carrier material comprises appropriate antibody to bind the cell, and various oligonucleotides for Gensequen ⁇ zen or SNPs.
  • FIG. 5 shows a schematic flow diagram of a production method for carrier materials.
  • the production of magnetic beads as a base material is ERAL ⁇ ner the art and described in advance. Accordingly, the magnetic beads are provided in a first method step Sl.
  • a second procedural ⁇ rens intimid S3 chemically reactive groups are applied to the net Mag- beads, which according to known also to
  • the magnetic beads are provided with affinity ligands in different coating solutions.
  • the chemically reactive groups enter into a covalent bond with the affinity ligands present in the coating solution.
  • further coating solutions can be run through until the surface of the magnetic beads is functionalized in accordance with the specifications.
  • concentration of Affini ⁇ tiquessliganden in the coating solutions should be selected so that the entire surface of the magnetic beads is after introducing the magnetic beads in the coating solution is not coated with the respective affinity ligands, but only a corresponding fraction. This leaves room on the surface for the further coating steps.
  • the desired affinity ligands are present in a mixture, so that all affinity ligands simultaneously bind to the surface of the magnetic beads.
  • the magnetic beads are described, for example, in procedural ⁇ ren for detecting particular nucleic acid sequences can be used.
  • So-called lab-on-a-chip systems are becoming increasingly important here. Such systems often consist of a disposable cartridge in which the sample is processed and analyzed in various process chambers connected by microchannels. A control unit, into which the cartridge is inserted, controls the analysis process in the cartridge.
  • the described magnetic beads to novel lab-on-a-chip systems can define and execute entspre ⁇ accordingly new analytical methods. Subsequently, an advantageous, largely automated method of analysis is described way of example with ⁇ , wherein the provided, multifunctional magnetic beads are advantageously used. It should be detected by the process specific cells in a sample, so as to create a diagnosis.
  • the sample is the patien ⁇ th filled through a filling opening of the cartridge.
  • the cartridge is then inserted into the controller, which automatically starts the analysis process.
  • a second process step in a processing chamber of a bond stored there with the magnetic beads to un ⁇ tersuchenden cells of the sample takes place.
  • the magnetic beads in the solution are moved back and forth by appropriate manipulation of a magnetic field to accelerate the process.
  • the process chambers of the cartridge are filled with water and there in dry
  • the magnetic beads by the Mag ⁇ netfeld be moved to a structure disruption chamber.
  • the cells bound to the magnetic beads are dissolved by a lysis buffer stored in the structure-in-solution chamber and flooded with water in solution and the DNA contained in them is liberated. Short-term heating of the lysis buffer denatures the DNA.
  • the lysis buffer may also be added to sodium hydroxide solution, which also has a denaturing ⁇ tion is achieved.
  • the released DNA molecules bind to the magnetic beads.
  • the antibodies are detached from the surface of the magnetic beads by a protease enzyme in the lysis buffer so that residues of the cell structures are no longer attached to the magnetic beads. Consequently, the magnetic beads are only connected to the DNA molecules of the cells to be analyzed.
  • the magnetic beads with DNA molecules are moved through a microchannel into a washing chamber of the device.
  • any residues of cells and other impurities are washed out.
  • the magnetic beads are moved into an amplification chamber.
  • a polymerase chain reaction is carried out in the amplification chamber and the DNA of the cells to be examined is thereby multiplied. To carry out the chain reaction, several temperature cycles between two temperatures are carried out in the amplification chamber by means of a Peltier element of the control unit.
  • the magnetic beads and the DNA fragments bound thereto are moved through a microchannel into a detection chamber of the cartridge.
  • hybridization of the DNA fragments with oligonucleotides arranged in the detection chamber takes place in an eleventh method step. Due to the specific binding properties, only those DNA fragments which are intended to be analyzed are attached to the oligonucleotides. These are therefore tailored specifically to the analysis of a particular cell type.
  • proof of hybridization takes place, for example, by magnetic detection of the magnetic beads. In particular, this detection method would possibly present from previous process steps and no longer required magnetic beads lead by their magnetic ⁇ stray stray field problems.
  • the provided multifunctional magnetic beads offer great advantages.
  • further purification steps may be provided, for example in a further washing chamber arranged between the processing chamber and the structure break-up chamber. It is also possible to arrange several wash chambers in succession in order to be able to carry out several washing steps in succession.
  • the method described above relates only to one type of DNA to be detected, for example from a specific virus. However, the process steps can also be parallelized in such a way that different types of DNA can be detected. It is then necessary to prepare provided magnetic beads and corresponding detection options. It is also necessary to align the PCR to several types of DNA.
  • RNA is converted by reverse transcription into so-called cDNA and can then be amplified by PCR and detected by the detection unit.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

Matière de support destinée à être utilisée dans un procédé diagnostique, qui est constituée d'une matière de base pourvue d'une surface (5) équipée d'au moins deux ligands d'affinité différents.
EP06763813A 2005-06-27 2006-06-21 Matiere de support et procede de fabrication et d'utilisation de ladite matiere Withdrawn EP1896853A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005029808A DE102005029808A1 (de) 2005-06-27 2005-06-27 Trägermaterial, Verfahren zu seiner Herstellung und Verwendung
PCT/EP2006/063394 WO2007000399A1 (fr) 2005-06-27 2006-06-21 Matiere de support et procede de fabrication et d'utilisation de ladite matiere

Publications (1)

Publication Number Publication Date
EP1896853A1 true EP1896853A1 (fr) 2008-03-12

Family

ID=36954238

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06763813A Withdrawn EP1896853A1 (fr) 2005-06-27 2006-06-21 Matiere de support et procede de fabrication et d'utilisation de ladite matiere

Country Status (4)

Country Link
US (1) US20100068823A1 (fr)
EP (1) EP1896853A1 (fr)
DE (1) DE102005029808A1 (fr)
WO (1) WO2007000399A1 (fr)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US40129A (en) * 1863-09-29 Egbert spencee
US23222A (en) * 1859-03-08 Samuel mcquerns and benjn
US14060A (en) * 1856-01-08 Pecr-cutteb
US259138A (en) * 1882-06-06 Upright drill
US221363A (en) * 1879-11-04 Improvement in buttons and studs
US18507A (en) * 1857-10-27 William henley
US219066A (en) * 1879-09-02 Improvement in mowing-machines
US4401764A (en) * 1980-02-07 1983-08-30 Technicon Instruments Corporation Immunoassays employing labeled reagent and a conjugate having two binding sites
CN1185492C (zh) * 1999-03-15 2005-01-19 清华大学 可单点选通式微电磁单元阵列芯片、电磁生物芯片及应用
DE10013995A1 (de) * 2000-03-22 2001-09-27 Chemagen Biopolymer Technologi Magnetische, silanisierte Trägermaterialien auf Basis von Polyvinylalkohol
US20030040129A1 (en) * 2001-08-20 2003-02-27 Shah Haresh P. Binding assays using magnetically immobilized arrays
EP1438398A2 (fr) * 2001-10-26 2004-07-21 Immunivest Corporation Analyse de parametres multiples d'acides nucleiques et de caracteristiques morphologiques d'ensemble sur le meme echantillon
US9435799B2 (en) * 2002-07-31 2016-09-06 Janssen Diagnostics, Inc. Methods and reagents for improved selection of biological materials
DE10321809A1 (de) * 2003-05-14 2005-03-17 Micronas Holding Gmbh Verfahren zum Drucken von Biomolekülen
WO2005094381A2 (fr) * 2004-04-01 2005-10-13 Rules-Based Medicine, Inc. Analyse universelle multiple

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007000399A1 *

Also Published As

Publication number Publication date
DE102005029808A1 (de) 2007-01-04
US20100068823A1 (en) 2010-03-18
WO2007000399A1 (fr) 2007-01-04

Similar Documents

Publication Publication Date Title
EP1896858B1 (fr) Dispositif et procede de preparation d'un echantillon pour une analyse et dispositif et procede d'analyse d'un echantillon
DE60122138T2 (de) Isolierung von nukleinsäuren
EP1894214B9 (fr) Particules magnetiques comportant une couche de silice fermee ultrafine, leur procede de production, et leur utilisation
DE102006002258B4 (de) Modul zur Aufbereitung einer biologischen Probe, Biochip-Satz und Verwendung des Moduls
DE60219040T2 (de) Dielektrophoretisches verfahren und anordnung für hoch-durchsatz screening
DE60316660T3 (de) Verwendung eines silikamaterials bei der amplifikation
DE69636553T2 (de) Nukleinsäuren bindender magnetischer Träger und Verfahren für die Nukleinsäureisolierung unter dessen Verwendung
DE60110256T2 (de) Verfahren zum konzentrieren von analyten in proben
DE69732708T2 (de) Magnetischer träger zur fassung von mikrosubstanzen und verfahren zur kontrolle des trägersstandorts
WO2008068181A1 (fr) Système pour préparer une pluralité d'échantillons pour une analyse
DE212013000295U1 (de) Vorrichtungen zum Einfangen von Zielmolekülen
EP1274745B1 (fr) Materiaux supports magnetiques et silanises, a base d'alcool polyvinylique
WO1999004239A2 (fr) Crayon magnetique pour la concentration et la separation de particules
WO2010012641A1 (fr) Appareillage et procédé de détection automatique de particules biologiques
DE102017204267A1 (de) Verfahren zur anreicherung von zellen aus einer probe und der nachfolgenden nukleinsäureisolierung aus diesen zellen
DE602004011448T2 (de) Poröse Medien
EP1242816B1 (fr) Materiau chromatographique et procedes d'utilisation d'un tel materiau
EP2411811B1 (fr) Superposition de phases pour la séparation de particules
EP4326438A1 (fr) Procédé de détection en ligne automatisée d'au moins une substance cible biologique dans un liquide et analyseur en ligne
WO2007000399A1 (fr) Matiere de support et procede de fabrication et d'utilisation de ladite matiere
EP3111220B1 (fr) Procédures pour diagnostics moléculaires pour enrichir un acide nucléique d'un échantillon biologique
EP3961212A1 (fr) Dispositif et procédé d'élimination de la biotine libre d'un échantillon liquide
WO2018011397A1 (fr) Procédé, nanoparticules et kit pour mettre en évidence des structures cibles
WO2009065620A2 (fr) Procédé d'extraction flexible permettant la production de bibliothèques de molécules spécifiques d'une séquence

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071120

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: EHBEN, THOMAS

Inventor name: SCHONECKE, MITJA

Inventor name: ZILCH, CHRISTIAN

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20101008

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOVILLE GMBH

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOVILLE GMBH

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140103